Mazdutide: Approved in China, Unknown Elsewhere
Mazdutide was approved in China in June 2025 for weight management. Learn how this GLP-1 and glucagon dual agonist works...
Evidence-based, medically reviewed articles on metabolic health, GLP-1 science, nutrition and sustainable weight management.
Mazdutide was approved in China in June 2025 for weight management. Learn how this GLP-1 and glucagon dual agonist works...
Prediabetes is reversible, and modest weight loss is the most effective intervention. South Asians develop diabetes at l...
Single, dual and triple agonists explained. Learn what GLP-1, GIP, glucagon and amylin each do, and why stacking recepto...
Unapproved weight loss peptides are sold openly online. Learn what "research use only" really means, what WHO data shows...
Some people should not take GLP-1 drugs at all, and others need specific precautions. Here is the complete list of contr...
Berberine is marketed as a natural Ozempic. Meta-analysis of randomised trials found no significant weight loss. Here is...
Standard eligibility is BMI 30, or 27 with a weight-related condition. But South Asian thresholds are lower, which chang...
The trial that made apple cider vinegar famous for weight loss has had its data formally questioned in published journal...
Eligibility changes at both ends of the age spectrum. Here is what applies to teenagers, older adults, and everyone in b...
Physician-authored articles on GLP-1, metabolism and sustainable fat loss, delivered to your inbox.
✓ Subscribed! Check your inbox.
No spam. Unsubscribe anytime.